Bevacizumab: As a VEGF Inhibitor
Created 4 weeks ago by marykudro

Bevacizumab is introduced as a VEGF (vascular endothelial growth factor) inhibitor. It is used for treating a number of types of cancers and specific eye diseases. For cancer, bevacizumab injection uses are recommended by slow injection into a vein (intravenous) and used for colon cancer, glioblastoma, lung cancer, and renal-cell carcinoma. In many of these diseases, it is used as first-line therapy. In order to treat age-associated macular degeneration, bevacizumab is recommended by injection into the eye (intravitreal). The bevacizumab injection is available as strengths of 100 mg/4 ml or 400 mg/16 ml.